Congratulations to Professor Anna Williams and Professor Tilo Kunath who have been appointed as Co-Directors of the Centre for Regenerative Medicine. Professor Williams is a Professor of Regenerative Neurology and Honorary Consultant Neurologist and Professor Kunath is a Chair of Regenerative Neurobiology. Both new Co-Directors have been Principal Investigators in the Centre from its very…
2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) have announced Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the annual Grand Challenges in Parkinson’s Disease symposium and parallel Rallying to the…
‘Access to Health’ to improve stroke care in Africa
New initiative from Merz Therapeutics and World Stroke Organization October 24th, 2024: at the annual World Stroke Congress in Abu Dhabi, the President of the World Stroke Organization (WSO), Dr. Sheila Martins, officially announced a partnership with Merz Therapeutics to launch the ‘Access to Health’ initiative. This project, focusing on addressing healthcare disparities in low-…
New research in glioblastoma
Merck & Co is buying Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on glioblastoma (GBM). This could “change the whole landscape,” said Ranjit Bindra, M.D., Ph.D., Modifi co-founder and physician-scientist at the Yale School of Medicine. GBM is the most common type of brain cancer and is a devastating disease,…
MHRA approves donanemab…
…but NICE says it does not demonstrate value for the NHS The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer’s disease in eligible adults in Great Britain. Eligible patients are limited to…
Fast track approval in Fabry disease?
Sangamo Therapeutics announces alignment with FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease: BLA submission expected in 2025 – U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time…
Bepranemab Phase 2a study
Results accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting 22nd October 2024: UCB today announced that the results of its double-blind TOGETHER (AH0003) Phase 2a study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild Alzheimer’s Disease (AD), have been accepted for presentation in…
Oditrasertib in multiple sclerosis – phase 2 trial stopped
Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The RIPK1 inhibitor was removed from the list of active studies after it failed to meet its primary and secondary endpoints. The belief was that inhibiting the kinase may stop tissue damage and neuronal death by disrupting the production of cytokines and other…
Lundbeck enhances neuroscience pipeline
Deal to acquire Longboard Pharmaceuticals gives access to Bexicaserin for Dravet Syndrome October 14 2024: H. Lundbeck A/S and Longboard Pharmaceuticals, Inc have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Through the acquisition of Longboard, Lundbeck gains access to…
